Upcoming Medical Conferences in La JollaSearch Criteria : United States of America La Jolla
Jan 10 - 12, 2019 | USD $650 | La Jolla, California
11th Annual T-cell Lymphoma Forum is organized by Jonathan Wood and Associates (JWA) and will be held from Jan 10 - 12, 2019 at Hilton La Jolla Torrey Pines, La Jolla, California, United States of America. The target audience for this medical event is hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma. Course Description: The T-cell Lymphoma Forum provides just the platform for attendees and world leaders in TCL to gather and exchange ideas and information to improve outcomes for this patient population. Plan to join our distinguished international faculty for this informative program. We invite all registered meeting attendees to submit abstracts for poster and/or oral presentation on their latest research in T-cell lymphoma, including global epidemiology, prognostic markers and tools, pathobiology, clinical management, global implications, immuno-oncology, molecular pathways, new therapeutic approaches, as well as cutaneous disease. A limited number of abstracts will be chosen for oral presentation during the meeting. There will be a Poster Walk Reception on Friday evening to highlight all abstracts selected for poster presentation. Price: Physicians and Healthcare Professionals: USD 650.0 Fellows/Residents/Nurses: USD 250.0 Pharmaceutical and Healthcare Industry representatives: USD 1350.0 Exhibitor Only: USD 450.0 Speakers: Francine M. Foss, Owen A. O'Connor, Won Seog Kim Additional details will be posted as soon as they are available.
Feb 02, 2019 | CME 7.75 | USD $125 | La Jolla, California
7th Annual Advances in Gastroenterology and Hepatology Conference is organized by UC San Diego School of Medicine (UCSD SOM) and will be held on Feb 02, 2019 at University Of California, San Diego, La Jolla, California, United States of America. Target Audience: This initiative is designed for gastroenterologists, primary care physicians, internal medicine physicians and other healthcare professionals who care for patients with GI issues. Accreditation: The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA: The University of California San Diego School of Medicine designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAPA: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 7.75 hours of Category 1 credit for completing this program. Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME. For the purpose of relicensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credit™ (report up to 7.75 hours of credit and list "CME Category 1" as the provider number). Course Description: This interactive one-day activity will present cutting-edge new opportunities for improving assessment and management of patients with gastrointestinal conditions, and place recent advances in context of current assessment and management paradigms. Specific topics that will be covered include: optimizing polyp detection and removal; colorectal polyp surveillance; Crohn's disease; pouchitits, autoimmune hepatitis; hepatocellular cancer screening; optimizing outcomes of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS); injury prevention for the endoscopists; autoimmune hepatobilliary disease; achalasia and achalasia variants; GI bleeding; cannabis therapy for gastrointestinal disease. The format includes keynote presentations by internationally known guest speakers, short, evidence-based updates by UC San Diego faculty, and interactive presentations and panel discussions of challenging cases. Educational Objectives: At the completion of this symposium, participants should be able to: • Implement current strategies for colorectal screening • Review updates to national colon polyp surveillance guidelines • Apply optimal approaches to identification and management of Crohn’s disease and pouchitis • Identify autoimmune hepatitis • Recall current evidence to support screening for hepatocellular carcinoma • Apply novel approaches to optimizing outcomes of ERCP and EUS • Examine the best approaches to diagnosing and managing hepatic encephalopathy • Apply strategies for avoiding endoscopist injury • Describe advances in diagnosis of autoimmune hepatobilliary disease • Identify approaches to identify achalasia and achalasia variants • Implement an evidence-based approach to the diagnosis and management of obscure GI Bleeding Assess the evidence for use of cannabis therapy to treat gastrointestinal disease.
Sanford Burnham Prebys (SBP) Insights: Heart Disease is organized by Sanford Burnham Prebys (SBP) Medical Discovery Institute and will be held on Feb 07, 2019 at Fishman Auditorium, La Jolla, California, United States of America. Conference Description: Wonder how cutting-edge scientific research leads to cures and pioneering treatments for patients? You are invited to explore the impact of medical research on the future of human health as we host an exciting new speaker series: SBP Insights. We will take an in-depth look at a wide array of diseases in need of a cure. Join scientists, doctors and patients as they discuss the latest breakthroughs in a panel discussion, followed by a Q&A session Additional details will be posted as soon as they are avaialable.
Feb 15 - 16, 2019 | CME 12.75 | USD $1300 | La Jolla, California
2019 Congress of Neurological Surgeons (CNS) Minimally Invasive Cranial Course is organized by Congress of Neurological Surgeons (CNS) and will be held from Feb 15 - 16, 2019 at UC San Diego Center for the Future of Surgery, La Jolla, California, United States of America. The target audience for this medical event is general practicing neurosurgeons. This CME Conference has been approved for a maximum of 12.75 AMA PRA Category 1 Credits. Course Description: This course is designed for the general practicing neurosurgeon who wish to introduce or expand the use of minimally invasive technologies and approaches to their cranial practice. The 2-day intensive course will include a combination of lectures, case-based discussions, and cadaver dissections. Topics covered will include: endoscopic evacuation of ICH, stereotactic navigation and exoscopic techniques for subcortical surgery, and laser interstitial thermal therapy for epilepsy and oncology indications. Learning Objectives: Upon completion of the course, attendees will be able to: • Evaluate spontaneous intracranial hemorrhage patients in terms of selection criteria for potential surgical management and apply case planning principles • Develop hands-on cadaver training experience for endoscopic evacuation of intracerebral hemorrhage • Gain familiarity with modern stereotactic navigation principles, relevant fascicular anatomy, and exoscopic technology platforms to facilitate sub-cortical surgery for varying pathologies and approaches • Identify indications for LITT management for epilepsy and oncology patients and review illustrative case examples
Feb 16 - 17, 2019 | CME 13.75 | USD $900 | La Jolla, California
2019 Modern Radiotherapy for Hematologic Malignancies is organized by American Society for Radiation Oncology (ASTRO) and will be held from Feb 16 - 17, 2019 at UC San Diego Altman Clinical and Translational Research Institute, San Diego, California, United States of America. Taregt Audience : This meeting is designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pediatric hematology-oncologists. This CME Conference has been approved for a maximum of 13.75 AMA PRA Category 1 Credits. Course Description: This Conference is a two-day meeting featuring interactive case discussions; educational sessions on the multidisciplinary care of patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, myeloma and leukemia; sessions discussing integration of new technology (i.e., IMRT, VMAT, deep inspiration breath hold, proton beam therapy); new targeted therapies; immunotherapy; treatment guidelines; supportive care; and oral abstract sessions highlighting the most current, evidence-based practices. The goal of this meeting is to provide participants with updates on current clinical and translational initiatives in hematologic malignancies that are relevant to daily clinical practice. Additionally, attendees will be updated on the appropriate integration of these advancements in their daily practice, including indication, patient selection, and combinations of different therapeutic modalities, and management of common toxicities. The program is expected to involve significant audience participation in an effort to adapt to the interest of the audiences and to provide a more meaningful and enjoyable experience. Course Objectives are: • Discuss the current guideline-based clinical practice in hematologic malignancies, in a case-based format. • Use case examples to apply current hematologic malignancies guidelines into clinical practice. • Discuss PET/CT response adaptive radiotherapy protocols for Hodgkin lymphoma and non-Hodgkin lymphoma. • Apply Involved-site radiotherapy (ISRT) for all disease sites - including Hodgkin lymphoma, and non-Hodgkin lymphoma. • Apply multidisciplinary care in hematologic malignancies for optimal outcomes and discuss the importance of multidisciplinary care with others. • Describe key advances in immunotherapy and targeted therapy in hematologic malignancies, and discuss special considerations when incorporating radiotherapy, keeping in mind potential overlapping toxicities. • Integrate recent advances in new technology (i.e., IMRT, VMAT, deep inspiration breath hold, proton therapy) and explain to others how and when to integrate them. • Describe key advances in imaging and its role in adaptive therapy protocols. • Distinguish how late effects of radiotherapy, balanced against emerging data on dose-dependent late effects of chemotherapy, affects decision-making. • Manage toxicities related to the management of hematologic malignancies. • Summarize key recent advances in the understanding of the biology of hematologic malignancies. Additional details will be posted as soon as they are available.
Feb 23, 2019 | CME 4.50 | La Jolla, California
Third Annual Clinical Advances in the Diagnosis and Management of Pulmonary Hypertension is organized by Scripps Health and will be held on Feb 23, 2019 at Schaetzel Center, La Jolla, California, United States of America. The target audience for this medical event is Cardiologists, Internists, Primary Care Practitioners, Nurses, Nurse Practitioners, Physician Assistants. This CME Conference has been approved for a maximum of 4.5 AMA PRA Category 1 Credits. Conference Description: This CME conference is designed to educate clinicians on state-of-the-art care for pulmonary hypertension. Pulmonary hypertension (PH) is a common and widely misunderstood syndrome that results from a surprisingly large number of disease processes. It can occur at any age and the risk of developing PH increases with age and other medical conditions. Great strides have been made in the past 15 years in diagnosing and treating pulmonary arterial hypertension (PAH) so that the natural history of PAH is rapidly changing. On the other hand, the more common clinical variant, pulmonary venous hypertension (PVH) has been largely unaffected by medical therapy. In addition, there is often a divide between those whose treat PAH and those clinicians whose patients have PVH and are frustrated by the lack of effective therapy. This conference will be unique in that it will cover all forms of pulmonary hypertension. Expert faculty will discuss the epidemiology of PH, how PH is diagnosed, and the poor outcomes associated with PH when left untreated. Clinicians will leave with a better understanding of the difference between PAH and PVH and why the difference matters. Therapies for PAH and PVH will also be discussed with reference to current clinical guidelines. Participants will return to their practice equipped with the latest evidence base and practical information to improve patient outcomes. Conference Objectives are: • Describe the epidemiology and pathophysiology of pulmonary hypertension. • Determine who is at risk for pulmonary hypertension and effectively diagnose patients. • Recognize the difference between PAH and PVH and how this translates into therapy. • Outline the current approach to pulmonary hypertension treatment in the presence of related or underlying diseases. • Evaluate current pharmacologic and medical management strategies for patients with pulmonary hypertension. • Incorporate novel therapies into patient care for improved outcomes. Identify when to refer patients for specialty treatment. Prices: Physicians: USD 100.0 Non-Physicians: USD 65.0 Speakers: J. Thomas Heywood, MD, FACC, Laith Alshawabkeh, MD, FACC, Steven J. Escobar, MD, Richard M. Keating, MD, Rajeev C. Mohan, MD, Demosthenes Papamatheakis, MD, Ajay V. Srivastava, MD, FACC Time: 7:30 am - 1:10 pm
Mar 03 - 06, 2019 | La Jolla, California
Advanced Course in Basic & Clinical Immunology is organized by Federation of Clinical Immunology Societies (FOCIS) and will be held during Mar 03 - 06, 2019 at Estancia La Jolla, La Jolla, California, United States of America. Course Description : Invited speakers are chosen based on their expertise in basic and clinical immunology, as well as their teaching skills. The lectures cover the major topics in cellular and molecular immunology, including innate immunity, B cells, T cells, dendritic cells, cytokines and mucosal immunity. Other lectures cover autoimmune, allergic and immunodeficiency diseases, as well as new advances in interventional and clinical immunology and the molecular and genetic basis of immunologically-mediated diseases. All lecturers encourage interaction with the students through questions and discussions during lecture time. There is also ample opportunity for students to interact with the faculty outside the lecture room. Target Audience : The target audience includes clinical fellows in disciplines related to immunology, including rheumatology, allergy, infectious disease, oncology and transplantation; fellows doing basic research with an emphasis on human disease; scientists or other research and development personnel from biotechnology and pharmaceutical companies who are involved in developing new therapies for immunological disease; and academic or community physicians who wish to enhance their understanding of immunology. Course Objectives : At the conclusion of this course, attendees will be able to: • Discuss the fundamental mechanisms underlying protective immune responses, and discuss the recent advances and emerging themes in immunology research. • Describe the fundamental mechanisms underlying immunologic disease and associate these mechanisms with strategies for therapeutic modulation of the immune system. • Appreciate the basic immunological principles underlying biotherapeutics, recognize the commonality among diverse organ-specific disease states and infer the mechanisms of therapeutic effect. • Analyze the medical literature reporting immunologic advances pertinent to their patients, cite the rationale for use of new immunodiagnostic and immunotherapeutic modalities in their patients, and serve as thought leaders within their medical communities. Additional details will be posted as soon as they are available.
Mar 08 - 10, 2019 | CME 13.50 | USD $375 | La Jolla, California
34th Annual New Treatments in Chronic Liver Disease CME Conference is organized by Scripps Conference Services & CME and will be held from Mar 08 - 10, 2019 at Estancia La Jolla Hotel & Spa, La Jolla, California, United States of America. The target audience for this medical event is Hepatologists, Gastroenterologists, Infectious Disease Specialists, Nurse Practitioners, Physician Assistants, Nurses, Residents/Fellows. This CME Conference has been approved for a maximum of 13.50 AMA PRA Category 1 Credits. Course Overview : This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, cholangiocarcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases. There was a fundamental change in the treatment of chronic hepatitis C in late 2014 with the addition of multiple new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on currently available all-oral therapies that have been approved and are currently in use. The second will be on the benefits of cure and post-cure management of patients with cirrhosis. In addition, the pre-conference will extensively detail currently available treatment regimens with the goal of introducing the topic to new treaters. In this past year, new treatments have been reported for both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). For this reason, we have invited Dr. Cynthia Levy, Assistant Director of the Schiff Center for Liver Diseases at the University of Miami, Miller School of Medicine to act as our William S. Haubrich Memorial Lecturer on these topics. The course will also review alcoholic liver disease and NASH, which have now surpassed chronic hepatitis C as the leading indications for liver transplantation in the United States. We have invited a world-recognized expert on alcoholic liver disease to update our knowledge of the topic this year. Although hepatitis B treatments have not changed, we now have more mature data available on long-term HBsAg loss and clinical outcomes. The addition of immune-mediated therapies for HBV with the goal of curing the disease will also be included in this year’s program. New therapies for NAFLD and NASH are in development and important new data showing positive results in NASH will be presented at this meeting, including the first results of a phase 3 global treatment trial. The explosive growth of NASH in the United States has created a significant need for effective drug therapy. A number of new systemic therapies for HCC that have been approved in the last two years will also be discussed. In addition, the course will provide updates on management of hepatic encephalopathy, hyponatremia, thrombocytopenia, and complications in the transplant candidate. Conference Objectives : • Understand the details of the AASLD guidelines for treatment of HCV using DAA’s in IFN-free regimens. • Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions. • Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals. • Discuss therapies for HCV including NS5A, protease and polymerase inhibitors. • Update the skills and management required for transplant hepatology. • Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients. • Discuss future treatment paradigms for HCV direct-acting antiviral drug. • Describe the diagnosis and treatment of PBC and PSC. • Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder. • Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia. • Review the management of complications beta-blocker therapy in ESLD. Conference Highlights : • Half day pre-conference seminar reviewing the virology, genotypes and modes of infection of HCV • Plenary talks from nationally recognized experts • Presentations on hot topics, upcoming scientific developments, and current advances in in chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease • Networking opportunities among colleagues • Conference app with access to course materials and recordings from the convenience of your mobile device or computer Time: 12:30 to 11:30 Speakers: Paul J. Pockros, MD, FACG, Scripps Clinic , Catherine T. Frenette, MD, FAST, AGAF, Scripps Clinic , Terry D. Box, MD, University of Utah School of Medicine, Paul Kwo, MD, Stanford University Medical Center, Cynthia Levy, MD, FAASLD, University of Miami, Miller School of Medicine, Michael R. Lucey, MD, University of Wisconsin School of Medicine and Public Health, Christian B. Ramers, MD, San Diego State University, School of Public Health, Yuki Rosenkoetter, PAC, MPAS, Scripps Clinic, Baylor College of Medicine, Norman L. Sussman, MD, Baylor College of Medicine, I. Raymond Thomason, MD, University of Utah, Zobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD, Inova Fairfax Hospital Center for Liver Disease
Apr 04 - 07, 2019 | USD $1495 | La Jolla, California
Trauma Basic Principles is organized by AO North America and will be held from Apr 04 - 07, 2019 at Hilton La Jolla Torrey Pines, La Jolla, California, United States of America. Course Summary: This Basic Course is designed to provide the participant with a fundamental knowledge of the operative treatment of fractures according to the AO principles. The four guiding AO principles of fracture fixation are: • Anatomic reduction of the fracture fragments, particularly in joint fractures • Stable fixation to ensure proper healing of the fracture allowing surrounding tissue to move and strengthen • Atraumatic surgical technique to preserve the blood supply to the bone fragments and soft tissue • Early, pain-free mobilization returning the patient to function as soon as possible. The course will cover the concepts of absolute and relative stability, as applied in context, of the soft tissue injury for each limb segment’s major fracture types. This course is the foundation for the AONA curriculum, which teaches the surgeon how to manage trauma and trauma reconstruction. The goal of this course is not to advocate the treatment of all fractures by surgical fixation, but rather to help ensure that when surgery is carried out, that it is done properly based upon principles, appropriate preoperative planning, and decision making. Learning Objectives: Upon completion, participants should be able to: • Discuss the concepts of stability, their influence on bone healing, and how to apply implants to achieve appropriate stability • Plan a treatment based on assessment, imaging, classification, and decision making • Apply reduction techniques in fracture management with attention to the importance of the soft-tissue • Apply related psychomotor skills to the practical application of orthopedic implants to fractured bones • Plan the initial treatment of the polytraumatized patient Additional details will be posted as soon as they are available.
Trauma Advanced Principles is organized by AO North America and will be held from Apr 04 - 07, 2019 at Hilton La Jolla Torrey Pines, La Jolla, California, United States of America. Course Summary: This Advanced Course will focus on the treatment of complex fractures and fracture complications. This will be accomplished through didactic presentations and group discussions between the participants and faculty. In addition, surgical techniques will be practiced on artificial bones. Topics will include complex fractures of the upper and lower extremities, fractures of the pelvis and acetabulum, fracture complications and polytrauma management. Participants will have the opportunity to address the treatment of malunions and nonunions, using preoperative planning and current fixation technique Learning Objectives: Upon completion, participants should be able to: • Apply reduction techniques in fracture management with attention to soft tissue • Assess and treat complex diaphyseal and (peri)articular fractures using advanced application techniques • Demonstrate strategies for assessing and treating open fractures and soft-tissue injuries • Initiate appropriate management for patients with pelvic injuries and polytrauma • Recognize complications and manage accordingly Additional details will be posted as soon as they are available.